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Abstract
Background: There is on-going controversy in relation to the efficacy of naltrexone used for the
treatment of heroin addiction, and the important covariates of that success. We were also
interested to review our experience with two depot forms of implantable naltrexone.
Methods: A retrospective review of patients' charts was undertaken, patients were recalled by
telephone and by letter, and urine drug screen samples were collected. Opiate free success (OFS)
was the parameter of interest. Three groups were defined. The first two were treated in the
previous 12 months and comprised "implant" and "tablet" patients. A third group was "historical"
comprising those treated orally in the preceding 12 months.
Results: There were 102, 113 and 161 patients in each group respectively. Groups were matched
for age, sex, and dose of heroin used, but not financial status or social support. The overall follow-
up rate was 82%. The Kaplan Meier 12 month OFS were 82%, 58% and 52% respectively. 12 post-
treatment variables were independently associated with treatment retention. In a Cox
proportional hazard multivariate model social support, the number of detoxification episodes,
post-treatment employment, the use of multiple implant episodes and spiritual belief were
significantly related to OFS.
Conclusion: Consistent with the voluminous international literature clinically useful retention
rates can be achieved with naltrexone, which may be improved by implants and particularly serial
implants, repeat detoxification, meticulous clinical follow-up, and social support. As depot
formulations of naltrexone become increasingly available such results can guide their clinical
deployment, improve treatment outcomes, and enlarge the policy options for an exciting non-
addictive pharmacotherapy for opiate addiction.
Introduction
Ever since the pathfinding studies in New York of Dole
and Nyswander [1] and colleagues methadone has been
the mainstay of the medical treatment of opiate addiction
of patients for whom detoxification and a drug free life-
style appears to be beyond reach. Indeed the successes of
agonist replacement therapy, first with methadone and
more recently with buprenorphine, have made agonist
replacement therapy something of a standard of care to be
sought in the treatment of other chemical addictions for
which treatment as yet either does not exist or is still in its
infancy. There are however increasing concerns in relation
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to the immunosuppressive activities of opiate [2,3] and
other addictive drugs [4,5,7], and there have long been
recognized significant cytostatic activities of opiates [8]
and other addictive agents [9,10] which oppose cell
growth and stem cell renewal which although less well
known are potentially also of significant medical concern.
Moreover there is increasing concern in the community
about the failure of methadone to lead to a long term sta-
ble drug free lifestyle including on-going drug use, drug
dealing and drug affected driving [11] together with very
high rates of psychiatric symptomatology [12,13]. For
practical clinical purposes however there has been little
alternative for patients for whom the lifestyle and health
issues or the legal constraints related to opiate addiction
make medical assistance mandatory.
Naltrexone is one alternative which has existed for several
decades but is rarely used. First synthesized by Matossian
at Endo laboratories in 1963 [14], it was trialed clinically
under sponsorship from the National Institute of Drug
Abuse (NIDA) in the early 1970's and a flurry of papers
were written documenting this experience. Naltrexone
itself has many useful features to assist the management of
opiate addiction including direct chemical blockade of
opiate use for up to three days after a dose, rapid cessation
of the symptoms of acute withdrawal syndrome once the
initial treatment induction is accomplished, reduction of
opiate craving in most patients [15-17], increasing the
time to relapse to dependent use up to three days from the
last administration, and in the experience of this clinic, a
great reduction in the frequency with which patients think
about addiction. The most well known of the early papers
is that by Hollister [18] which although encouraging in
terms of reporting 20% treatment retention at 7 months
compared to 13% in the placebo group with many other
positive adjustments in patients' lives, was felt to demon-
strate a disappointingly low rate of retention in treatment.
Similarly most of this early literature is similarly unenthu-
siastic. The major reason for this appears to be a lack of
patient compliance outside of select groups such as physi-
cians and parolees, perhaps because it does not have the
addictive attraction of agonist medications, but also
related to concerns of overdose and mood depression
management [19,20]. Another feature of this literature is
that, following the agonist literature, much of it reports
treatment retention rather than non-return to dependent
opiate use. Whilst this is standard practice with studies of
agonist medications, non-compliance with the oral medi-
cation is not necessarily the same as dependent drug use.
Studies which report "opiate free success" generally give a
much more robust view of antagonist based treatment
than those which focus solely on the former index [21-
23].
It has been hoped that many of these compliance prob-
lems will be overcome by the recent development of
depot formulations of long acting naltrexone injections
and implants [24]. This was recognized very early by the
National Institute of Drug Abuse which as long ago as
1976 [25] and 1981 [26] published research monographs
on the subject of depot and long acting formulations of
the drug. Several long acting depot injections with activity
over about one month have recently been developed [27]
and marketed in the USA [28] mainly for alcohol [29-31],
but are also likely to find application in opiate dependent
patients. More recently a longer acting device efficacious
for 4–6 months [32] and used widely in Australia for opi-
ate dependency has been developed and trialed, and is
presently under consideration before the regulatory
authorities in this country. Contrary to the classical view
of the limited clinical role of naltrexone [33] several fasci-
nating papers have emerged from researchers in Perth and
elsewhere in relation to the use of the depot formulation
in the pregnant heroin user with improved outcomes over
agonist therapy [34]; the addicted anesthetist [35]; pro-
longed maintenance of therapeutic serum naltrexone lev-
els above 1–2 ng/ml with sequential implants of 13–17
months [36]; potentiation of the antiviral effect of combi-
nation therapy for Hepatitis C [37] and HIV [38,39] pos-
sibly by an immunopotentiating mechanism and a
dramatic truncation of overdose behaviour in high risk
frequently overdosing heroin addicts [40] to the point
where the earlier concerns in relation to the safety profile
of naltrexone have been largely addressed [41-44]. Other
centres have a similar encouraging experience with the use
of such preparations in opiate dependency [24,28,45,46].
We were therefore interested to compare our early experi-
ence with a one month depot device from the USA, to the
"Go Medical" implant from Perth, and to compare this
experience in turn with the concurrent and historical
experience with the oral formulation of naltrexone. Some
of these results, and important lessons for patient man-
agement which follow from them, are presented in the
following report. Serum levels of naltrexone, serious
adverse events, and the experience with buprenorphine in
the office management of opiate dependent patients are
presented in companion papers.
Methods
Patient Population
The study was performed on patients presenting to a low
cost private naltrexone clinic in Brisbane, Australia. The
program had been in operation for over three years at the
time the study was performed. Patients were divided into
three groups on the basis of when they were treated and
the primary treatment modality employed. Patients were
not randomized. Group selection during the later period
was mainly made on financial status, determined by theSubstance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
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ability of patients' families to afford the implants. The
three groups defined were:
1) "Implant": Patients having a naltrexone implant March
2000 – March 2001. Some of these implant patients had
first been treated at earlier time points;
2) "Tablet": Patients treated with oral naltrexone March
2000 – March 2001;
3) "Historical": Patients treated with oral naltrexone 12
months prior to the recent period, March 1999 – March
2000.
In order to control for the effects of the passage of time it
was felt important to keep the two oral naltrexone groups
separate for most of the analysis as indicated, particularly
in view of the changing heroin supply in Australia over the
period of this study.
Psychosocial Markers
Assignments of various psychosocial indicators was made
by the treating clinician based on information disclosed
during the time of patients' presentations to the clinic,
and documented by retrospective review of patients'
charts. Financial status, social support and spiritual belief
were assigned in three groups. Patients' financial status
was assigned into three strata: "pensioner" relating to
those on social security alone; "average" relating to those
in socioeconomic class III-V, and "white collar" relating to
those in socioeconomic class I-II. The strength of social
support networks were graded 1, 2 or 3 depending on the
availability of mature adult responsible carers in the
patients life, and the access of the patient to those carers.
Sport and employment variables were assigned on a sim-
ple presence or absence basis. For the purposes of urine
drug screening, the most recent result in the patient's file
was the one analyzed. Spirituality was defined as religios-
ity and was assigned on the basis of declaration of belief
in traditional religious belief (Buddhist, Hindu, Moslem
or Judeo-Christian) (scored "2"), traditional belief and
consistent practice (scored "3"), or nil, atheist or pagan
(scored "1").
Rapid Opiate Detox
The Rapid Opiate Detox and induction onto naltrexone
was performed after the method of O'Neil which is similar
to that approved by the NSW Health Department [47,48].
This involves two days opiate free preparation with cloni-
dine and diazepam and other agents, and then the incre-
mental administration of naloxone from 40 mcg IVI after
a premedication with flunitrazepam, clonidine, ondanset-
ron, octreotide and other drugs, and then the incremental
administration of naltrexone, performed over 8–12 hours
in a primary care setting.
Naltrexone Preparations
Oral naltrexone tablets were used. These are the 50 mg
"Revia" tablets from Du Pont, obtained in Australia from
the Orphan Drug company. It was a condition of treat-
ment in this clinic that all patients presenting for naltrex-
one treatment brought with them a responsible mature
adult drug free carer who could supervise oral tablet
administration on a daily basis, or assist with the implant
process where that option was chosen. Implants were
obtained from two sources both presently provided as a
pre-loaded syringe. The American implants are a single
pellet containing 1 g of naltrexone and were obtained
from the Wedgewood Pharmacy, 405 Heron Dr. Suite
200, Swedesboro, New Jersey, USA, 08085-1749. The Aus-
tralian implants contain 1.1 g naltrexone, and release
about 0.4% of their dose daily. It was obtained from "Go
Medical" in Perth, 200 Churchill Ave, Subiaco, Western
Australia, Australia, 6008. It is also presented as 10 pellets
in a sterile pre-loaded syringe.
Implant Technique
Naltrexone implants were inserted subcutaneously after
the method of Brewer. The implant may be inserted at any
time after the commencement of naltrexone when the
patient is stable and restful. In essence implant insertion
involves the use of sterile surgical technique and local
anaesthesia (with lignocaine and bupivicaine "Marcaine"
and adrenaline) to make a 1.5 cm incision in the skin, and
the development of a 10–12 cm. long subcutaneous tun-
nel by blunt dissection. The sites chosen may vary, but the
most suitable are the skin of the lower abdomen or the lat-
eral chest wall with an incision below the hair of the
axilla. The pre-loaded syringe is then inserted into this
space and the contents discharged. The skin is closed with
two or three vertical mattress sutures.
Follow-up
The period of follow-up was defined as one month before
and after 1st March 2001. Patients were followed up either
in the normal course of their clinical review protocol, or
for patients who had ceased clinic attendance, by formal
recall by telephone and in writing. The date of the last nal-
trexone purchase was also obtained and factored into the
calculation of the patient's likely clinical status. Urine
samples and independent reports from their carer were
used to verify patients' self-report. A carer was defined as
a mature responsible drug free adult who was able to
supervise the administration of all medication, and partic-
ularly to crush the naltrexone tablet daily and supervise its
administration. The primary measure of satisfactory
progress in these patients was "opiate free success." This
was defined as a composite measure including having a
urine drug screen negative for opiates by Thin layer Chro-
matography or having a carer report satisfactory progress.
The date of final contact was taken as the latest of the lastSubstance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
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clinic visit, the last telephone contact, or the last naltrex-
one tablet to be purchased, as determined by pharmacy
records. As reported below it was possible to follow up
most patients. However where patients could not be fol-
lowed up positively every patient was assigned a score
based on how it was believed they had progressed, either
on the report from their family, or the report from other
patients in their network. Patients for whom no data was
available or who were known to have relapsed to regular
heroin or methadone use were presumed to have failed
treatment.
Data and Statistics
All data was obtained by retrospective review of patient
charts after deliberate follow-up as described. Data was
entered into Microsoft Excel spreadsheets. It was analyzed
by several programs, particularly the survival and failure
time analysis module of Statistica. The modes used in this
module were the two sample, k-samples, and Cox propor-
tional hazard multivariate models. Key statistics calcu-
lated were the WW statistic, the sum of scores of the
differences between R1 and R2 being the number of scores
below and above each score respectively, and Gehan's
modification of the Wilcoxon test statistic. The statistical
programs EpiInfo (CDC Atlanta, Georgia), the Mann-Ken-
dall test for trends [49,50] including calculation of the
Sens estimate for quantification of trends on the software
of the University of Linkoping, Sweden [51] and the Finn-
ish Meteorological Institute [52] were also employed. The
major data output form was the Kaplan Meier Survival
Curve which was generated from this data and used to
illustrate rates of opiate free success. The default statistical
test for significance between different Kaplan Meier rates
was Gehan's Wilcoxon test. Multivariate analysis in the
Survival Analysis module was by Cox's proportional haz-
ards model in the three groups defined above. P < 0.05
was considered significant.
Ethical Statement
This study was undertaken as part of a retrospective clini-
cal audit of patients treated under semi-urgent conditions.
Implant patients were treated under the special provisions
of the Australian Special Access Scheme of the therapeu-
tics Goods Administration in Canberra A.C.T., Australia.
The study was approved by the clinic Human Research
Ethics Committee, National Health and Medical Research
Council registration number #000409. No procedure was
performed on patients which would not have been done
in the normal course of their clinical care. All patients
were treated with their own informed witnessed consent.
Only disidentified aggregated data is presented.
Results
There were 102, 113 and 161 patients in each of the
implant, tablet and historical groups respectively, a total
of 376 patents. Various follow-up and demographic crite-
ria are presented in the accompanying Table 1. The mean
ages, mean duration of opiate use, sex distribution, and
doses of heroin used were as indicated. There were no sig-
nificant differences between the groups on these indica-
tors. In the following discussion the consecutive ordered
triplets refer to the implant, tablet and historical groups
respectively.
When however the financial and social status of the three
groups were compared significant differences were
revealed between the various groups. These various ratios
are given in the later part of Table 1. Note that the groups
were not assigned randomly. Based on a numbers in the
"Pensioner" category, the differences in financial means
from the implant group were significant. There were more
Table 1: Sociodemographic profiles of three groups
IMPLANT TABLETS HISTORIC
General Features
Follow-up Rate 88.2% 72.6% 83.7%
Age (years) 26.1 26.2 26.7
% Male 68% 65% 68%
Years IVDU 5.5 4.5 5.2
Dose Heroin (g) 0.59 0.53 0.47
Financial Status
% Pensioners 9% 29% 18%
% SES III-V 64% 59% 71%
% SES I-II 27% 12% 10%
Social Support
Weak 2 5 %2 %3 4 %
Average 51% 82% 58%
Strong 25% 16% 8%Substance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
Page 5 of 15
(page number not for citation purposes)
patients in the pensioner category in the tablet group (Chi
Squ. = 68.48, df = 1, O.R. = 18.15, 95% C.I. = 7.85 – 43.20,
P ≤ 0.001), and the historical' group (Chi Squ. = 12.54, df
= 1, O.R. = 3.77, 95% C.I. = 1.66 – 8.77, P = 0.0004). The
combined differences from the implant group were signif-
icant at (Chi Squ. = 37.52, df = 1, O.R. = 7.59, 95% C.I. =
3.53 – 16.83, P ≤ 0.001). The variables of social support
were also distributed differently. The implant group
appeared to have the largest number of patients in the
"strong" category. Compared to the tablet group this dif-
ference was not significant (Chi Squ. = 2.87, df = 1, O.R. =
1.78 95% C.I. 0.87–3.68, P = 0.09), but compared to the
larger historical group it was significant (Chi Squ. = 14.65,
df = 1, O.R. = 3.84 95% C.I. 1.78–8.42, P = 0.001). When
both groups were analyzed together the difference was sig-
nificant (Chi Squ. = 11.29, df = 1, O.R. = 1.42, 95% C.I.
1.42–4.92, P = 0.0007). These baseline sociodemographic
differences should be borne in mind in the consideration
of all subsequent results.
The follow-up rate was 82% overall. The overall urine
drug screen follow-up was 76%. The proportion of
patients in each group whose urine tested positive for nal-
trexone was 70%, 52% and 39% respectively and 50.4%
overall. The re-treatment rate of all patients attending this
clinic is 1.4 (1301 treatments in 902 patients). The num-
bers of patients having various numbers of implants is
indicated in Table 2. The re-implant rate in the present
series was 24.5% (25 of 102 patients having more than
one implant; and 102 patients having 141 implants).
Figure 1 shows the proportion of patients complying with
treatment by the various treatment groups. Figure 1A
shows the outcome by the three treatment groups. Figure
1B illustrates the respective outcomes by the two implant
and two tablet groups conflated. Figure 1C shows the out-
comes by the four treatment groups including the two dif-
ferent implant groups. When a statistical analysis was
done of the type of implant used including no implant,
there was a significant difference (Chi squared = 20.93, df
= 3, P = 0.001). However when the two implants alone
were compared the difference was not significant (WW =
90.00, Gehan's test statistic = 0.77, P = 0.43). Figure 1D
shows the outcome by the presence or absence of naltrex-
one in the urine (WW = 1961.0, Gehan's test statistic =
2.4089, P = 0.1600).
Table 3 lists the urine positivity rates for various illicit
drugs. The rate of obtaining a urine drug screen (UDS) for
assessment in the three groups was 98%, 70% and 76%
respectively. The dominant drug used was cannabis, fol-
lowed by amphetamines. Amphetamine use was signifi-
cantly greater in the implant group than either the tablet
(Chi Squ. = 7.13, df = 1, O.R. = 2.78, 95% C.I. =
1.22–6.42, P = 0.0075) or historical (Chi Squ. = 11.14, df
= 1, O.R. = 3.28, 95% C.I. 1.52–7.18, P < 0.001) groups.
Amphetamine use was significantly elevated in the
implant group post-treatment compared to the two oral
groups combined (Chi Squ. = 13.83, df = 1, O.R. = 3.05,
95% C.I. 1.60–5.83; P = 0.0002).
Table 4 lists the improvement in work status before and
after treatment for the three groups. There was a signifi-
cant improvement in the implant and tablet groups, but
not in the historical group. If the analysis is performed on
all three groups as three groups the employment status
improved from 35% prior to treatment to 54% afterwards
(Chi Squ. = 27.57, df = 5, O.R. = 2.24, C.I. 1.65–3.09, P <
0.001).
Review of spiritual status of patients after treatment
revealed that 65%, 26%, and 9% scored 1, 2 and 3 respec-
tively, with no significant differences in between group
distribution.
Table 5 lists detailed outcome data by various treatment
parameters. Figure 2 shows the outcome for selected psy-
chosocial variables, and Figure 3 illustrates outcomes for
selected treatment variables. Table 6 lists the bivariate sig-
nificance of these various relationships. Dichotomous
and multiple response variables have been analyzed in
closely related but differing statistical modules within the
software giving rise to the varying statistics presented for
each variable. The following variables are significant on
bivariate analysis: post-treatment employment, the
number of detox's, social support, the use of implants
rather than tablets, and the number of implants adminis-
tered (all P ≤ 0.001), the treatment group in which
patients were, the type of implant (as discussed above),
financial status, the presence of morphine on urine drug
screen, spirituality, olanzepine on urine testing, and nal-
trexone urine positivity were all significant (P < 0.05).
Other variables identified were not significantly related to
outcome. It is noteworthy that the trend for the number of
implants was of borderline significance (S-score = 8, Sens
slope estimate 8.44, Mann-Kendall statistic = 1.959, P =
0.0500) and for the number of detox's was highly signifi-
Table 2: Numbers of implant procedures performed
NO.'s IMPLANTS NO. PATIENTS
17 7
23 6
31 2
48
81
TOTAL 141
RE-IMPLANTATION RATE: 25/102 = 24.5%Substance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
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cant (S-score = 19, Sens slope estimate = 14.56, Mann-
Kendall statistic 2.853, P = 0.0043) as illustrated for both
variables in Figure 4.
Clearly however the central issue relates to relative impor-
tance of these various factors. A multivariate survival anal-
ysis was performed which demonstrated that social
support, the number of detox's, work after treatment, type
of implant, the number of implants and spirituality con-
tinue to be significant. When a similar analysis was per-
formed limited to implant patients alone, social support,
work prior to treatment and the presence of cannabis in
the urine were significantly related to opiate free success.
Discussion
This study has been performed as part of an ethically
approved clinical audit of the opioid treatment program
in this clinic and makes pertinent comparisons between
rates of opiate free success in patients treated with implant
Opiate Free Success by Figure 1
Opiate Free Success by: A.: Combined Oral Tablet and Implant Group; B: Perth, USA, Tablet and Historical Groups. C.: Pres-
ence or Absence of Urinary Naltrexone. **** – P < 0.0001; ** – P < 0.025.
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Table 3: Urine positivity rates (%) of different illicit drugs
Drug Implant Tablet Historic
Amphetamine 31 14 12
Morphine 4 5 16
THC 50 39 34
Cocaine 1 0 0
Methadone 1 1 7Substance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
Page 7 of 15
(page number not for citation purposes)
and orally administered naltrexone as well as a variety of
psychosocial and treatment parameters. Factors which
were noted on bivariate analysis to be significant were in
order were employment subsequent to treatment, the
number of detox episodes, the level of social support, the
number of implant episodes, whether implants or tablets
were used, the use of multiple implants, the type of
implant (including no implant), spirituality, the financial
status of the family unit, the presence of morphine in the
urine, the presence of naltrexone in the urine, negatively
correlated with the presence of olanzepine in the urine
and the semi-quantitative presence of naltrexone in the
urine (Table 6). On multivariate regression the significant
variables were the strength of social support, the number
of detox episodes, work after treatment, the type of
implant (including none), the use of multiple implant
episodes, and spiritual belief. When the multiple regres-
sion was limited to implant patients alone the only varia-
bles of significance were social support, work prior to
treatment and the presence of cannabis in the urine. In
this group the number of implants was of borderline sig-
nificance (P = 0.06).
Table 4: Work status before and after R.O.D.
BEFORE AFTER WEIGHTED O.R. 95% C.I. SIGNIFICANCE LEVELS
IMPLANT 18% 50% 4.67 2.35–9.33 <0.001
TABLETS 25% 48% 2.78 1.52–5.09 <0.001
HISTORIC 53% 60% 1.36 0.85–2.16 0.178
OVERALL 35% 54% 2.24 1.65–3.09 <0.001
These tests were Chi squared tests. Rows 1–3 had one degree of freedom, and row four had five degrees of freedom.
Table 5: Detailed outcome statistics for opiate free success for selected treatment variables
Median Mean Std. Dev. % Completed % Censored Total N
No. Detox's
1 15.29 23.09 24.64 38.74 61.26 222
2 55.00 53.82 30.07 35.38 64.62 65
3 55.00 61.43 30.00 40.00 60.00 45
4 76.86 78.56 35.66 30.77 69.23 13
5 66.86 78.19 34.35 18.18 81.82 11
6 95.29 95.66 21.45 25.00 75.00 8
7 126.64 126.64 1.92 50.00 50.00 2
Total 25.00 39.04 34.45 366
No. Implants
0 27.29 40.22 35.73 46.72 53.28 274
Single 16.29 28.32 27.57 18.18 81.82 77
Multiple 57.71 56.07 32.49 8.00 92.00 25
Total 25.00 38.84 34.57 376
Type of Treatment
Historicals 56.86 48.83 36.94 55.28 44.72 161
Tablets 21.57 27.96 30.06 34.51 65.49 113
USA 17.14 30.59 28.68 16.67 83.33 78
Perth 51.36 49.84 34.56 12.50 87.50 24
Total 25.00 38.84 34.57 376
Urinary Naltrexone
Absent 36.00 43.48 36.33 47.06 52.94 85
UDS + 30.14 43.75 35.95 27.54 72.46 69
UDS ++-++++ 24.00 37.96 32.76 27.93 72.07 111
Total 27.29 41.24 34.75 265
Note on Table interpretation. The first three columns of this table list the days of opiate free success. "Completed" observations refers to patients 
whose clinical course has been determined be there time of follow-up. Censored observations refer to those patients still in treatment at the time 
of follow-up, and whose final outcome in treatment therefore remains to be determined at a future time point.Substance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
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With the increasing availability of long acting and depot
preparations of antagonists onto the pharmaceutical mar-
ket some guidelines for their application would be most
useful. It must be noted in considering the outcome anal-
ysis of this study that the form of the present work was a
retrospective chart review. Patients were not randomized
and there were notable differences between the groups at
enrolment in social support and financial status which
were related to having to fund the cost of the treatment
including implants. Given this important limitation there
are a number of indications from this data which are use-
ful for directing clinical practice, and may be tested in well
designed randomized clinical trials. Strengths of this
study included the relatively high overall follow up rate of
82%, the relatively large patient numbers reviewed, the
breadth of treatment and psychosocial factors examined,
and the various formulations of naltrexone used.
The major point of this study is the remarkable success of
sustained implant therapy. 88% of the Perth implant
patients and 78% of the USA implant patients were opiate
free at 12 months. Our data clearly indicates that repeated
episodes of detoxification and of implant insertion are
important contributors to opiate free success and to the
long term engagement with patients whose long term
course is recognized to be marked by periodic relapse.
This notable success rate suggests a potential alternative to
other management streams for refractory opiate depend-
ence such as rehabilitation where places are typically lim-
ited, and incarceration with all its attendant costs and
problems. This latter option has been extensively dis-
cussed [53,54].
We did not find a difference in the two types of implant
used. Whilst this may be due to considerations of statisti-
cal power, the null hypothesis cannot be confidently
excluded on the basis of the present data. It is noteworthy
that the surgical procedure for implant insertion is
straightforward. Since this study was completed the usual
technique has changed in that rather than precipitate an
acute detoxification syndrome under sedation using oral
or parenteral antagonists as described here, a generally
milder procedure is performed where the implant itself is
used to detoxify the patient. As the serum levels achieved
with the subcutaneous route are lower than those seen
with alternative routes in well prepared patients, this tech-
Table 6: Bivariate correlations of opiate free success. Kaplan – Meier survival curves. All patients.
Parameter WW Chi Squared Gehan's – Wilcoxon 
Test Statistic
Degrees Freedom P
Work After 6582.0 5.1978 0.00000
No. Detox's 39.1498 6 0.00000
Social Support 34.5710 2 0.00000
Implants or Tablets 6427.0 4.4719 0.00001
No. Implants 22.2834 2 0.00001
Group 20.4844 2 0.00004
Type of Implant 20.9302 3 0.00011
Financial Status 16.3870 2 0.00028
Morphine +UDS 18.4386 3 0.00036
Spirituality 19.5863 2 0.0006
Olanzepine +UDS 7.8996 2 0.01927
Naltrexone Simplified +UDS 6.0243 2 0.0492
Ecstacy +UDS 5.3881 3 0.14551
Cannabis Bivariate 1199.0 -1.3281 0.18416
Sport After 1324.0 1.0902 0.27561
Benzodiazepine +UDS 2.1997 2 0.33293
Cannabis Trivariate 1.7659 2 0.41357
Olanzepine Simple 458.00 1.9468 0.51156
Amphetamine + UDS 0.9888 2 0.60994
Heroin/Methadone -392.0 0.4169 0.67676
Citalopram +UDS 306.00 0.3537 0.72353
Citalopram Bivariate +UDS 0.3563 2 0.83683
Work Before -245.0 -0.1958 0.84477
Male Sex 72.000 0.0469 0.96255
Note: This table combines statistical results for dichotomous variables and also variable with multiple responses. The Chi squared and degrees of 
freedom columns apply to the dichotomous variables, and the WW and Gehan's test statistic columns apply to variables with multiple categories. 
Drug levels in urine have been "simplified" or combined into composite trivariate categories to aide statistical analysis by combining levels of ++ to 
++++ as simply ++. Parameters are presented as ordered by significance of the P-value.Substance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
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Impact of Selected Psychosocial Variables on Opiate Free Success Figure 2
Impact of Selected Psychosocial Variables on Opiate Free Success: A.: Social support; B.: Post-treatment employment status; 
C.: Financial Status; Spiritual Belief; E.: Pre-treatment employment status; F.: Sporting involvement. *** P < 0.001; **** – P < 
0.0001.
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Impact of Selected Treatment Variables in Opiate Free Success Figure 3
Impact of Selected Treatment Variables in Opiate Free Success: A.: No. of detox episodes; B.: No. implant episodes; C.: Single 
vs. multiple implant episodes; D.: Urinary naltrexone levels; E.: Urinary citalopram levels; F.: Urinary olanzepine levels. * – P < 
0.05; ** – P < 0.025; **** – P < 0.0001.
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nique is easier and much faster, and suited to ambulatory
use.
We were pleased to note a 54% opiate free success rate for
tablet administration which is higher than that reported
from many other centres. However it should be noted that
this figure includes supervised and assisted administra-
tion of the tablet by a significant other individual, opiate
free success rates rather than simply retention only, and
repeated episodes of detoxification and treatment initia-
tion. Whilst this is a very different design from most nal-
trexone studies in the literature, it is nonetheless normal
practice in both other addiction pharmacotherapies and
most drug free rehabilitation programs. Careful involve-
ment of the residual functional social network is an
important buttress to pharmacological treatment, includ-
ing supervision of the taking of the oral tablet, crushing
the tablet and intensive medical supervision of minor side
effects in the early post-treatment period, which all appear
to be important to optimize results. The involvement of
supervision might explain the classical rather paradoxical
perception that naltrexone appears to work best for pro-
fessionals and recent prisoners [55], which stereotypically
represent the highest and lowest end of the social spec-
trum.
The literature experience with SSRI antidepressants
appears mixed [56,57]. In the present project no useful
effect was found. The presence of olanzepine in urine cor-
related negatively with opiate free success, which is not
surprising given its use in psychotic and the most severe
mood disorders. The elevated rate of amphetamine usage
amongst the implant cohort is of concern, albeit not per-
haps unexpected given the persistence of the ritual of
intravenous drug use in a milieu in which opiate use is
abruptly truncated. Unpublished data suggests that
amphetamine use shows a steady decline after an initial
surge after implant insertion (O'Neil personal communi-
cation) and our results would be consistent with this pat-
tern. It is likely that one of the major triggers to stimulant
use is the physical exhaustion which follows a an induced
detoxification period but further work is required to delin-
eate the natural history of such activity amongst implant
patients, and this is understood to be an area of active
investigation at this time.
The significant and dramatically increased rates of work
involvement after treatment is gratifying. This is also of
therapeutic importance in that it was shown to correlate
with success in both univariate and multivariate regres-
sion. Privileged financial status (as defined in the Meth-
ods section) whilst having some bearing on success in a
bivariate study, was shown not be significant when treat-
ment success was controlled for social support and spirit-
uality, which appeared to be the proximate underlying
and determinative variables.
The prominence of spirituality in the statistical analysis of
this study is of some interest. This area is increasingly
becoming a focus of research interest in recent times
[58,59]. Probably in common with most drug dependent
cohorts, the major religious affiliation of these patients
was "not involved/no belief". As this clinic had only four
Muslim families and two Hindu in the present sample, the
major religion or background of these patients was Chris-
tian which is in keeping with the major religious frame-
work in Australia. The strong effects persisting on
multivariate analysis are of interest. They may in part be
related to the inclusion of a category of religious life prac-
tice and consistency in this rating in which drug use was a
factor. The salience of this factor in this study is consistent
with previous demonstrations of the centrality of an holis-
tic understanding both of the psychopathology of addic-
tion and of the road to recovery [60,61,63], the
acknowledged success of 12-step programs, with classic
statements on the centrality of religion to character forma-
tion and development [64] and also with the enduring
holistic definition of Health itself as proposed by WHO
Significant Treatment Trend Analysis Figure 4
Significant Treatment Trend Analysis: A.: Detox episodes; B.: 
Implant episode numbers
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[65]. Spiritual pursuits offer obvious mechanisms to cope
with the some of the major issues of the psychological
agenda for recovery including refuge and solace, peace,
joy, coping with stress and guilt, values and virtue trans-
formation, as well as an alternative source for the elusive
paradise and esoteric pathway sought by many [66].
As mentioned above this paper does not discuss adverse
outcomes which are addressed in a companion study. In
general terms it can be said that this clinic has not encoun-
tered a mortality concern with these long acting implants
in the present experience no patient has died related to
causes which are attributable to the implant. A useful mar-
gin of safety however must form a pillar of successful
adoption of a new treatment if it is to be widely deployed.
The recent study of the Perth cohort by Hulse was noted
above, and the overall mortality risk of naltrexone
implant management was shown to be at least as low as
that of methadone maintenance [44]. A further and very
reassuring data source of interest was a recent Australia
wide study which examined all coronial reports in the
whole country which mentioned naltrexone implants. Of
the several thousand Perth implants which have been
used in Australia, only a single case was identified where
a naltrexone implant was plausibly temporally implicated
in the mode of death in which metamphetamine and
cocaine metabolites were also present and the level of nal-
trexone measured in the serum suggested a problematic
assay technique.
There are several limitations of the above study. Some of
these relate to the design limitations of a clinical audit
review. These would include the non-randomized nature
of the study, the use of historical controls, and the need of
patients to provide both drug free carers to supervise their
treatment, and to fund the costs of their treatment them-
selves. One limitation mentioned above was the smaller
numbers of patients with Perth implants which may have
lacked statistical power to define a difference between the
two implant types. There are several indications that the
experience reported herein is preliminary in that this
clinic lacks associated services which may be found with
larger programs such as counsellors, integrated Hepatitis
C care, gynecological care [67] and assisted accommoda-
tion entry, all of which would ideally be part of a demon-
stration or pilot program, and may receive consideration
for inclusion in a formal randomized trial.
A further physiological point of some interest is the gen-
eral consideration of the health effects of naltrexone,
which in general may be said to be opposite to those of
opiates. The effect on tissue growth and cell division are of
particular interest although they would appear to have
received little research attention [68]. In this regard the
recent demonstration in four genome wide screens in
three reports that the locus most strongly associated with
coronary artery disease on the human genome encodes
the two cyclin dependent kinases P16INK4A and
P15INK4B is fascinating [69-71]. It is relevant to the
present therapeutic study by virtue of the known potenti-
ation of apoptosis [72-76] and impairment of cell growth
by addictive drugs [77-79] which together suggest an
effect to accelerate the ageing process, and by the demon-
strated effect of naltrexone to reverse such effects on cell
growth [80]. Furthermore evidence of an acceleration of
the atherogenesis by addictive drugs has been published
in recent years from Johns Hopkins hospital [81], and the
NIH intramural laboratories [82], from the National Drug
and Alcohol Research Centre in Sydney [83] and has been
confirmed in this clinical population (unpublished obser-
vations). Indeed biochemical, immune and haematologi-
cal evidence for such a progeroid effect of addiction was
recently published [84].
Evidence of quantitative circulating stem cell deficits in
addiction [85], together with clinical evidence of stem cell
deficiencies in hair [86], bone [87] and teeth [88] together
with substantial impairment of body growth [89] have
recently been reported. In the study of dental pathology
[88] morphine and methadone dose were shown in mul-
tivariate regression to be significant correlates of the disor-
der of erosive periodontitis in which both immune and
stem cell components are believed to play major roles.
That naltrexone might reverse such an effect [90,91], and
that this may be demonstrable by assay of the classical
molecules of cell growth [92]and senescence [93,94] in
somatic and stem cell tissues is an intriguing possibility,
well worth further investigation in view of the elevated
rate of many pathologies in addiction [95] and the rapid
age related accrual of hepatic, cardiac, pulmonary, renal
and multi-system pathology amongst decedent IVDU's
[83], not to mention the very high mortality associated
with long term substance dependence [96,97]. A recent
comment by the scientific leaders of addiction medicine
that indeed the lead candidates involved in nicotine
addiction were molecules involved in intracellular
machinery is a further intriguing clue in this regard [98].
Conclusion
In summary, this study confirms extensive literature expe-
rience that both oral and implantable naltrexone can be
used with gratifying results in a primary care setting. Open
access to affordable treatment appears to be important to
ensure maintained success rates. The observed 12 month
opiate free success rate of 54% with tablets could possibly
be raised to 82% by the use of subcutaneous implants.
Whilst it seemed to the clinician involved that the longer
lasting Perth implants may be superior to those which are
presently in more widespread use, the present study evi-
dently lacked sufficient statistical power to show this.Substance Abuse Treatment, Prevention, and Policy 2007, 2:35 http://www.substanceabusepolicy.com/content/2/1/35
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Ready access to repeat treatment and particularly repeat
depot implantation would appear to be key components
of a program seriously endeavoring to deliver high quality
outcomes, and would appear to have the capacity to dra-
matically raise the treatment potential and patient appeal
of naltrexone therapeutics. It is important not to overlook
likely benefits to health of such medium term opiate
antagonism including immunostimulation and recovery
of cellular growth and organismal dysfunction which is
likely to have accrued over a period of drug dependency.
Employment after treatment, cannabis use, and spiritual
development were all shown to be significant. It would
seem likely that in the future implants will become the
route of administration of choice for naltrexone. Subse-
quent to the completion of successful trials in the USA
and Perth, extension of these findings in opiate depend-
ent populations in prospective randomized multicentred
trials would appear to be the logical next step for research
and development in this area. Long acting injections, and
depot delivered antagonists for other drugs of addiction
appear to potentially hold therapeutic promise and might
prove to be the way of the future.
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